Anderson Varejao Will Miss Remainder of Season Due to Blood Clot

Alex Kay@AlexPKayCorrespondent IJanuary 23, 2017

Nov 30, 2012; Atlanta, GA, USA; Cleveland Cavaliers center Anderson Varejao (17) drives to the basket in the first half against the Atlanta Hawks at Philips Arena. Mandatory Credit: Daniel Shirey-USA TODAY Sports
Daniel Shirey-USA TODAY Sports

The Cleveland Cavaliers are going to have to go the rest of the 2012-13 NBA season without Anderson Varejao.

This is according to an official press release by the team (via

Varejao recently developed a blood clot (small right lower lung pulmonary embolism) and was admitted to the Cleveland Clinic last Thursday (January 17th). … He will need to remain on blood thinning medication for approximately three months. While Varejao is expected to fully recover, he will miss the remainder of the current Cavaliers season.

It’s a shame that one of the best bigs in the league continues to remain sidelined with unfortunate medical ailments. Prior to the discovery of this blood clot, the Brazilian had been out of the lineup since Dec. 19, and on Jan. 10 he underwent surgery for a split in his quadriceps that was supposed to keep him on the bench for at least six to eight more weeks.

The 30-year-old center contributed in 25 games during the 2012-13 campaign and was averaging 14.1 points and 14.4 rebounds per game in what was looking like the best year of his career.

To add insult to injury, Varejao is reportedly (h/t ESPN's Marc Stein) going to miss out on a $1 million bonus for not making the East’s All-Star team this season—a feat he was more than likely going to achieve due to his solid statistics for a slumping Cavs team:

Varejao's latest injury REALLY painful. All-Star berth AV was in line for pre-surgery, I'm told, woulda triggered $1 mil bonus in contract

— Marc Stein (@ESPNSteinLine) January 16, 2013

Before heading out with the quad issue, Varejao was a hot topic in early trade talks. The veteran big is owed $8.4 million this season, $9.1 million in 2013-14 and has a team option for the final year of his deal worth $9.8 million.

While that could be considered a bargain for a contender that needs production in the post, the Cavaliers aren’t looking to pay a premium when they aren’t playoff-bound.

This blood clot all but ensures that Cleveland will wind up with yet another early lottery pick, as the team is just 10-32 at the halfway mark of the season. Only the 8-30 Washington Wizards have a worse winning percentage in the league.

It’ll be interesting to see what path the Cavaliers decide to travel with Varejao next year. There is a chance they continue to dangle him as trade bait around the draft and into the offseason, and they could likely find a taker as long as the recovery is going well.


For more details on how the blood clot will affect Varejao, check out B/R's report from Sports Injuries Lead Writer Will Carroll.